06 January 2010
A comparative evaluation of local anaesthesia for cataract surgery, published in The Journal of Cataract & Refractive Surgery says that randomized clinical trials are needed to facilitate statistical methods of metaanalysis to establish convincingly the overall benefits and efficacy of the various local anesthesia procedures in cataract surgery.
 |
19 August 2009
Allergan Inc. expects its ketorolac tromethamine ophthalmic solution 0.45% (Acuvail) to be available in the United States in September. The preservative-free formulation of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the treatment of pain and inflammation after cataract surgery and received FDA approval at the end of July, the company announced.
|
19 August 2009
Researchers in Cleveland have discovered the first gene associated with the formation of age-related cataracts. EphA2 encodes an enzyme that plays a role in the repair of proteins in the lens of the eye after they become damaged and clump together, according to the investigators.
|
19 August 2009
Results from the Omeros Corporation for the Phase I/Phase II clinical trial of OMS302, a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis) are said to be promising.
|
05 August 2009
ACUVAIL (Allergan), the ketorolac tromethamine ophthalmic solution, which acts as a treatment for inflammation and pain after cataract surgery has been approved by the FDA.
|
08 July 2009
Implementation of novel techniques to analyze the fluidic signature of phacoemulsification performed using different ultrasound modalities and phaco tips is providing important insights that will be helpful for improving the efficiency and safety of lens removal surgery.
|
13 May 2009
The cataract surgery technology landscape including pipeline products at varying development stages comes under scrutiny in a new report released this month.
|
06 May 2009
Visiogen is reporting significant progress in the development of the Synchrony IOL, including the completion of the US phase III study, the formation of Visiogen Europe GmbH and the commencement of commercialization in Europe.
|
25 March 2009
When treating post-phacorefractive keratectomy (PRK) discomfort, there are no significant differences in either safety or efficacy between bromfenac twice-daily and ketorolac four times daily, according to a study published in the February issue of the Journal of Refractive Surgery.
|
| 
